SINGAPORE, Sept. 29, 2014 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, today announced that its new configuration of LFS scintillation crystals (LFS-3 plates) will be assessed by CERN scientists in the Large Hadron Collider. As previously announced on July 28, 2014, the Compact Muon Solenoid (CMS) Experiment successfully tested the specially designed LFS-3 plates. Due to the high quality performance of the individual plates, the scientific team at CERN has ordered enough LFS-3 plates to build initial modules which will be installed in the Large Hadron Collider and subjected to a high energy beam.
"We have successfully made it to the final technical evaluation stage before approval can be given for full adoption of our LFS-3 plates for large scale CERN experiments," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "High light yield and radiation tolerance are the key performance criteria of our LFS-3 plates, and we expect to see the new design meet the strict parameters required by CERN experiments. We very much look forward to playing a major role in the advancement of scientific research at CERN and for Zecotek to be able to capitalize on the unique commercial value of its patented LFS scintillation crystal."
The CMS Experiment is one of two large general-purpose particle physics detectors built on the Large Hadron Collider at CERN in Europe. It is composed of three main components: scintillation material, photo-detectors and the ubiquitous electronic system. Zecotek's new LFS-3 plates are prime candidates for use in CERN's high energy experiments because of their density of material, stopping power, fast decay time, very good energy resolution, and radiation hardness. Experiments can also benefit from Zecotek's LFS-3 plates due to reduced labour and re-calibration costs associated with single crystal forms, as well as reduced interruptions associated with the maintenance and refitting of damaged crystals.
In March 2013, CERN scientists confirmed that a new subatomic particle discovered at the world's most powerful particle accelerator is the Higgs Boson. As CERN pushes into this new frontier of science, additional experiments are required to determine the particle's properties and its true form. High-energy scintillation crystals with high radiation hardness and solid-state photo detectors are paramount for the success of the next stage of experiments.
About the CMS Experiment at CERN
CMS is one of two general-purpose experiments at CERN's Large Hadron Collider (LHC) that have been built to search for new physics. CMS is designed to detect a wide range of particles and phenomena produced in the LHC's high-energy proton-proton and heavy-ion collisions. At CMS, scientists are looking into the unknown and trying to answer the most fundamental questions about our Universe, for example: "What is the Universe really made of and what forces act within it?" and "What gives everything substance?". CMS also measures the properties of well-known particles with unprecedented precision and is on the lookout for completely new, unpredicted phenomena. Such research not only increases our understanding but may eventually spark new technologies that could change the world we live in. The CMS experiment is one of the largest international scientific collaborations in history, involving 4300 particle physicists, engineers, technicians, students and support staff from 179 universities and institutes in 41 countries. For more information about CMS please visit http://cms.web.cern.ch.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit www.zecotek.com, follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and clean technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2013.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
SOURCE: Zecotek Photonics Inc.
For further information:
Zecotek Photonics Inc.
Unit 1120 - 21331 Gordon Way
Richmond, BC V6W 1J9
T: (604) 783-8291